The intramuscular administration of the complex of tris(2-hydroxyethyl)amine with zinc bis[(2-methylphenoxy)acetate] (Zitrimin), as an aqueous solution in a dose of 10 mg (kg of animal weight)?1 for 2 months decreases activity of lysosomal lipolytic hydrolase (EC 3.1.1), cholesterol esterase (EC 3.1.1.13). Hence, the previously unknown feature of Zitrimin, that is, the ability to inhibit cholesterol esterase, attests to both structural and functional disorders of subcellular structures during development of atherosclerosis. The agents active towards such reactions can be useful in this case. Owing to the new properties, Zitrimin can be used to increase the vascular system stability to cholesterol during the atherosclerotic process. This expands the scope of applicability of this compound and gives prospects for development of new Zitrimin-based drugs for preventing the atherosclerotic vascular changes.
相似文献The previously unknown ability of Zitrimin, the complex of tris(2-hydroxyethyl)amine with zinc(ii) bis(2-methylphenoxyacetate), to affect the activity of acid lipase of the aortic intima was studied. Daily administration of an aqueous solution of the tris(2-hydroxyethyl)amine complex with zinc bis(2-methylphenoxyacetate) in a dose of 10 mg kg?1 for 3 months to rabbilts with experimental atherosclerosis was found to decrease the cholesterol and total lipid levels in the aortic tissue and to decrease the degree of aortic damage with atherosclerotic plaques. According to the results of enzymatic analysis, development of atherosclerosis is accompanied by 68% increase in the activity of acid lipase in the intima of the aorta compared to the control.
相似文献